AD NET COHORT

Istituto Neurologico Carlo Besta

Fabrizio Tagliavini

email
fabrizio.tagliavini@istituto-besta.it

27/07/2022
1 Collaborating Centers

- Fondazione Santa Lucia IRCCS (Roma)
- IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli (Brescia)
- IRCCS Don Carlo Gnocchi (Firenze)
- IRCCS Ospedale San Raffaele (Milano)
- Università di Brescia
- Università di Perugia

2 Cohort Description

Age Range: 55-80
Size N: 426 subjects
Recruitment: march 2017 - march 2018
Data collection: 2017-2020
Healthy controls: yes
Only at-risk gene carriers included: no
Diseases studied:

- Alzheimer Disease (AD)
- Subjective Cognitive Complaints (SCC)
- Mild Cognitive Impairment (MCI)
- Pre - MCI (Jack CR Jr et al., 2012)
- Mild Alzheimer disease dementia (McKhann et al., 2011)

Clinical Evaluation:

- Neuropsychological Assessments (tests performed): Mini Mental State Examination, Clinical Dementia Rating, Brief Intelligence Test, Trial Making Test A-B, Motor Timing Task, Operation Span, Adaptation of Hayling Sentence Completion Test, Free and Cued Selective Reminding test, Rivermead Behavioural Memory Test, Rey Auditory Verbal Learning Test, Rey–Osterrieth complex figure (copy and recall), Sternberg Item Recognition Paradigm, Screening for Aphasia in Neurodegeneration, Phonetic and Semantic fluency test, Battery for Analysis of Aphasic Deficits, Naming and Comprehension tasks (CAGI test), Block design - WAIS-IV, Overlapping Figures - Birmingham Object Recognition Battery, Theory of Mind Picture Stories Task
- Behavioural Assessments (tests performed): Nottingham Extended ADL Scale, Everyday cognition scale, Cognitive Function Instrument, Independent Living Skills Survey,
Hollingshed, Beck Cognitive Insight Scale, Anosognosia Questionnaire-Dementia, Neuropsychiatric Inventory, Starkstein Apathy Scale, Symptom Checklist-90-R, Structured Interview for Prodromal Syndromes, Cerad Disphoria, Hamilton Anxiety Rating Scale, Hamilton Depression Rating Scale, Coping Orientation to Problems Experienced – Brief, Resilience Scale for Adult

**Imaging and Neurophysiology:**

- MRI 3 T
- FDG-PET
- Amyloid PET (for a subsample)

**Genotyping:**

- abca7, apoe, app, bin1, c9orf72, calhm1, ccl2, ccnf, cd33, chchd10, chmp2b, clu, cr1, csfr1r, cst3, ctsf, dctn1, fnc, fus, gba, grn, hnrnpa1, hnrnpa2b1, itm2b, lab, lrrk2, mapt, ncsnt, nos3, notch3, optn, pf1, pld3, prkar1b, prnp, psen1, psen2, serpini1, sigmar1, snca, sncb, sorl1, sqstm1, sth, tardbp, tbk1, tmem106b, trem2, tuba4a, tyrobp, ubqln2, vcp

**Digital Data obtained from patients through electronic devices:** no

**Biological Samples:**

- CSF
- DNA
- Plasma
- Urine
- Serum
- PAXgene tube

**Follow-up:**

- Number of Follow-ups planned: 3
- Number of Follow-ups completed: 3
- Average duration between follow-ups (years): 1
- Follow-ups type: Clinical evaluation and MRI (for a subsample of MCI)